Evidence map›Paper›PMID 28390570›Full record

ReviewRheumatic diseases clinics of North America2017

Menopause and Rheumatic Disease.

Mitali Talsania, Robert Hal Scofield

Abstract readReview
In one paragraph

Review in Rheumatic diseases clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. The Impact of Menopause on Autoimmune and Rheumatic Diseases.Clinical reviews in allergy & immunology · 2025
    Review
  4. Article
  5. Article
  6. Zuogui and Yougui pills improve perimenopausal syndrome regulation of apoptosis in mice.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Aqueous Extracts ofPharmaceutics · 2020
    Article
  17. Review
  18. Article
  19. Sex and autoimmune disease: Four mechanisms pointing at women.Mediterranean journal of rheumatology · 2019
    Review
  20. Sex and Management of Rheumatoid Arthritis.Clinical reviews in allergy & immunology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Mitali TalsaniaSection of Endocrinology, Diabetes and Metabolism, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, 1000 Lincoln Blvd, Oklahoma City, OK 73104, USA.
Robert Hal ScofieldSection of Endocrinology, Diabetes and Metabolism, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, 1000 Lincoln Blvd, Oklahoma City, OK 73104, USA; Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 Northeast 13th Street, MS 24, Oklahoma City, OK 73104, USA; Medical Service, Department of Veterans Affairs Medical Center, 920 NE 13th Street, Oklahoma City, OK 73104, USA. Electronic address: hal-scofield@omrf.ouhsc.edu.
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI TIMOTHY M VANWAGONER · 2013 to 2026
$68.2M
Pathogenic B Cells in Sjogren's SyndromeP50AR060804 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI SIVILS, KATHY L. · 2011 to 2015
$7.9M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7M
Sex Chromosome Aneuploidies in Autoimmune DiseaseI01BX001451 · VA · OKLAHOMA CITY VA MEDICAL CENTER · PI SCOFIELD, ROBERT HAL · 2012 to 2025
–
BLRD VA I01 BX001451NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P50 AR060804NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

Menopause occurs naturally in women at about 50 years of age. There is a wealth of data concerning the relationship of menopause to systemic lupus erythematosus, rheumatoid arthritis, and osteoarthritis; there are limited data concerning other rheumatic diseases. Age at menopause may affect the risk and course of rheumatic diseases. Osteoporosis, an integral part of inflammatory rheumatic diseases, is made worse by menopause. Hormone replacement therapy has been studied; its effects vary depending on the disease and even different manifestations within the same disease. Cyclophosphamide can induce early menopause, but there is underlying decreased ovarian reserve in rheumatic diseases.

Indexed as

MenopauseAntirheumatic AgentsArthritis, RheumatoidCyclophosphamideFemaleHumansLupus Erythematosus, SystemicOsteoarthritisOsteoporosis, PostmenopausalRheumatic DiseasesAntirheumatic AgentsCyclophosphamideMenopauseOsteoarthritisRheumatoid arthritisSystemic lupus erythematosus

Identifiers

PMID28390570
PMCPMC5385852
OpenAlexW2604969813

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.